NAUT · Nasdaq · ·
Next earnings: October 26, 2026
$1.36+22.0%Sep 29 close
Nautilus Biotechnology, Inc. is scheduled to report next on October 26, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$14.5M | -$15M | +3.75% |
| Profit per share | -$0.11 | -$0.12 | +8.33% |
| Free Cash Flow | -$14.2M | -$13.7M | -3.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nautilus Biotechnology, Inc. has no earnings call transcript available.
“The second quarter reinforced our ever-increasing conviction that proteoforms deliver critical biological resolution that Nautilus is uniquely positioned to deliver,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio Special Note Regarding
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nautilus Biotechnology, Inc.’s Item 2.02 8-K filed July 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.